Aussie super funds hit the jackpot in $2b biotech deal

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
The Manila Times

Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced ...
PharmExec

Novartis to Acquire Myricx Bio for $1.1 Billion

Novartis is buying Myricx to internalize an NMTi-based ADC payload platform intended to expand ADC applicability and ...
Hoodline

Swiss Drug Giant Drops $1.1 Billion On Quiet Boston Biotech Bet

Swiss pharma heavyweight Novartis is cutting a very large check. The company has agreed to acquire London-headquartered ...

Novartis scoops up UK biotech Myricx in $1.5 billion cancer push

Novartis AG NVS has agreed to acquire privately held U.K. biotechnology company Myricx Bio in a deal valued at up to $1.5 ...
The Manila Times

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class ...
The Next Web

Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class

Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.